我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
隶属于 the bank of new york mellon corp. (investment management)
相关临床试验
22
6 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
2000
进行中（未招募）
6
27.3%
已完成
8
36.4%
招募中
5
22.7%
终止
2
9.1%
撤回
1
4.5%
暂无批准数据
- Curis has activated eleven clinical sites for patient enrollment in its Phase 2 TakeAim CLL study evaluating emavusertib combined with zanubrutinib in chronic lymphocytic leukemia. - The company reaffirmed guidance that the initial five patients will be dosed by the end of July 2026, with initial data expected in December 2026. - The combination strategy targets dual blockade of NF-kB, a key driver of CLL, by pairing an IRAK4/FLT3 inhibitor with a BTK inhibitor. - Stockholders approved a reverse stock split at a ratio between 1-for-5 and 1-for-25 to help the company regain compliance with Nasdaq's $1.00 bid price rule.
